Sheba Medical Center

Sheba Medical Center, located in Tel Hashomer, Israel, is widely recognized as one of the leading healthcare institutions in the Middle East and among the top hospitals globally. Known for its excellence in clinical care, research, and innovation, Sheba has built a strong international reputation.

In 2013, the hospital received the prestigious Joint Commission International (JCI) Gold Seal of Approval, reflecting its commitment to high standards of patient care and safety. In 2019, it was ranked among the top ten hospitals worldwide by Newsweek and has consistently maintained this position in subsequent annual rankings.

Sheba Global Infrastructure

Sheba Medical Center is a large-scale healthcare campus comprising seven major facilities:

• Cancer Center
• Medical Education Academic Campus
• Medical Research Complex
• Acute Care Hospital
• Children’s Hospital
• Women’s Hospital
• Rehabilitation Hospital

Annual Patient Volume

• 430,000 inpatients
• 1,600,000 outpatients
• 200,000 emergency visits
• 50,000 surgical procedures
• 12,000 births annually
• 4,000,000 medical tests

Highly Specialized Centers

Jusidman Oncology Hospital

A cornerstone of cancer care in Israel, Jusidman Oncology Hospital is a leading center for advanced cancer treatment and research.

Treatment Philosophy

1. Multifaceted Therapy
Combining multiple treatment approaches such as chemotherapy, radiotherapy, and immunotherapy to achieve optimal outcomes with minimal side effects.

2. Personalized and Precise Therapy
Each treatment plan is tailored based on:

• Age and genetics
• Cancer type and stage
• Medical history and overall health
• Family history

3. Continuous Research and Innovation
Ongoing clinical trials and research initiatives ensure access to the latest therapies.

4. Compassionate Care
Holistic support addressing medical, psychological, and emotional needs of patients and their families.

Oncology Team

A multidisciplinary team of specialists including:

• Oncologists
• Surgeons
• Radiologists
• Pathologists

Treatment options include:

• Immunotherapy
• Chemotherapy
• Radiotherapy
• Surgical interventions

Diagnostic Excellence

Sheba provides:

• Advanced imaging (MRI, CT, Ultrasound)
• Laboratory diagnostics
• Precision oncology testing

Cancer Types Treated

The center treats a wide spectrum of cancers, including:

• Breast, lung, liver, and pancreatic cancer
• Brain and spinal tumors
• Blood cancers (including bone marrow transplantation)
• Prostate, ovarian, and uterine cancers
• Skin cancers including melanoma
• Gastrointestinal cancers (colon, stomach, esophageal)
• Thyroid and endocrine cancers
• Sarcomas and rare cancers

Cancer Center Key Statistics

• 50,000 cancer patients treated annually
• 4,500 new cases each year
• 35,000 outpatient treatments annually
• 37,000 visits to oncology clinics
• 2,000 new radiation therapy patients per year
• 270 patients receive brachytherapy annually

MD Anderson Partnership

Sheba Medical Center is an official sister institution of MD Anderson Cancer Center (USA), one of the world’s leading cancer hospitals.

This collaboration supports:

• Joint research programs
• Clinical training and education
• Quality assurance initiatives
• Faculty exchange programs

Pancreatic Cancer Center

The largest pancreatic cancer center in Israel, offering advanced and personalized care.

Available Treatments

• Whipple Procedure
• Total Pancreatectomy
• NanoKnife (Irreversible Electroporation)
• Chemotherapy and targeted therapy
• Radiation therapy
• Palliative surgeries

HIPEC – Hyperthermic Intraperitoneal Chemotherapy

For patients whose gastrointestinal, ovarian, or appendiceal cancer has spread within the abdominal cavity — a pattern that leaves few options with standard intravenous chemotherapy — Sheba offers hyperthermic intraperitoneal chemotherapy (HIPEC), a combined surgical and chemotherapy technique. Hundreds of patients have already undergone the treatment at Sheba.

HIPEC follows cytoreductive surgery (CRS), in which all visible tumors and lesions are surgically removed. Because CRS cannot remove microscopic remnants of cancer, the abdominal cavity is then bathed for 60–90 minutes in a concentrated chemotherapy “wash” heated to 42°C (107.6°F) — a dose up to 20 times higher than standard IV chemotherapy can safely deliver, made possible because the drug is applied directly rather than through the bloodstream. A laparoscopic, minimally invasive approach to HIPEC is also available at Sheba, allowing eligible patients to leave the hospital after just a few days without surgical drains.

“HIPEC was originally used only for cancer of the appendix and mesothelioma, two relatively rare diseases. However, in the last decade HIPEC has been applied to metastatic cancer in the abdominal cavity originating in the colon, stomach, and ovaries,” says Prof. Aviram Nissan, Director of the Department of Surgery C at Sheba.

Who Is a Candidate for HIPEC?

• Metastatic cancer confined to the peritoneal cavity, without spread to distant organs, confirmed by chest/abdomen CT or PET-CT
• Good functional status, free of significant kidney or cardiovascular disease

Without treatment, patients with extensive abdominal-cavity tumor spread typically survive 5–12 months. Published outcomes show HIPEC, combined with complete surgical removal of visible tumors, substantially outperforming conventional chemotherapy or surgery alone — giving patients previously considered incurable a realistic chance at extending their life expectancy. Because of the complexity of the surgery, Sheba emphasizes that both the pre-operative assessment and the procedure itself are carried out by a team specializing specifically in this technique.

Sheba Cancer Research Center (SCRC)

The largest cancer research facility in Israel, focused on developing innovative therapies and advancing oncology science.

Key Research Programs

• Molecular Cytogenetics
• Bioinformatics
• Tumor Stem Cell Biology
• Pediatric Oncology Research
• Immuno-Oncology
• Cancer Epigenetics
• Genomic Applications in Oncology

CAR-T Cell Therapy for Leukemia and Lymphoma

CAR T-cell therapy reprograms a patient’s own white blood cells to hunt down and kill cancer cells. Sheba performs the entire process on-site: white blood cells are collected from the patient, sent to a specialized laboratory where they are engineered to express chimeric antigen receptors (CARs) targeting the patient’s specific cancer, multiplied to millions of cells, and then infused back into the bloodstream — where the modified cells continue attacking the tumor for months or even years after a single treatment.

Who Is a Candidate?

CAR-T is provided to leukemia and lymphoma patients who have undergone at least two previous treatments. At Sheba, therapy is offered for acute lymphocytic leukemia (ALL) in adults and children, non-Hodgkin lymphoma (NHL) in adults and children, and multiple myeloma.

Outcomes

CAR-T has been especially effective in younger patients: young children have achieved a total recovery rate of about 85–90%, and roughly 80% of teenagers receiving the treatment have made a complete recovery from their leukemia. Across the total patient population, the success rate is approximately 70%.

Unlike conventional chemotherapy, CAR-T is given as a single infusion rather than repeated sessions, so most patients avoid the nausea, vomiting, and hair loss typically associated with chemotherapy. Serious complications, when they occur, are usually temporary, appear within the first one to two weeks after treatment, and are managed with medication by Sheba’s specialized team.

Care is led by Prof. Arnon Nagler and Dr. Abraham Avigdor of the Division of Hematology and Bone Marrow Transplantation for adult patients, and by Prof. Amos Toren and Dr. Elad Jacoby of the Pediatric Hemato-Oncology and BMT Department for children.

CAR-T Cell Therapy for Autoimmune Disease

Sheba is also translating CAR-T’s success in oncology into a pioneering research program for severe, treatment-resistant autoimmune conditions, including systemic lupus erythematosus, rheumatoid arthritis, Sjögren’s syndrome, scleroderma, dermatomyositis, and vasculitis.

This is a research and compassionate-use program, not a routine or broadly available treatment. Beyond formal clinical trials, Sheba has developed a self-manufactured CAR T-cell therapy offered under compassionate use for the most critical cases — a program the hospital describes as unique worldwide. It has already treated patients with advanced rheumatoid arthritis who had exhausted all available biologic treatments and were severely disabled; these patients showed strong clinical results, documented in a published case report. Sheba was also selected, alongside other leading Israeli medical centers, to participate in Israel’s national CAR-T initiative, and is the country’s leading rheumatology clinical-trial hub.

Because this program treats the most severe, refractory cases on a compassionate-use and research basis, eligibility is evaluated individually by Sheba’s clinical team following review of a patient’s full treatment history.

Ella Lemelbaum Institute for Immuno-Oncology

The largest and most advanced melanoma institute in the region, the Ella Lemelbaum Institute for Immuno-Oncology is a globally recognized center specializing in melanoma and skin cancer — including advanced, metastatic cases that have had little or no benefit from conventional therapies.

Treatments Offered

• Tumor-infiltrating lymphocyte (TIL) immunotherapy
• Fecal microbiota transplant
• Immunopheresis
• Immune checkpoint inhibitors
• Targeted therapy
• Chemotherapy
• Surgical oncology

Sheba is a leader in TIL immunotherapy, in which a portion of the patient’s tumor is removed, its infiltrating lymphocytes are isolated and grown to very large numbers in Sheba’s own laboratory, and then reintroduced into the patient’s body to hunt down tumor cells. About 50% of treated patients show improvement, and approximately 25% are cured of their melanoma. Sheba’s doctors have participated in TIL research from its earliest stages, and every part of the process — including the lymphocyte genetic engineering — is performed in-house at a single facility.

“Usually, within 4 weeks, we see the beginning of the clinical results. In the CT scans, you see the metastasis getting smaller and smaller, and some of the metastasis finally disappear. If you achieve complete response, it’s durable, and you actually cure patients with advanced melanoma,” says Prof. Jacob Schachter, Director Emeritus of the Ella Lemelbaum Institute for Immuno-Oncology.

Two additional therapies are available for patients who have not responded to immunotherapy. Fecal microbiota transplant introduces bacteria from melanoma patients who have responded to treatment into patients who have not, on the premise that changing the composition of the digestive tract’s bacteria can make a previously non-responsive patient receptive to immunotherapy. Immunopheresis uses a specialized filter to selectively remove immune-suppressive cytokines produced by cancer tumors, aiming to neutralize the tumor’s ability to block the patient’s natural immune defenses; unlike drug-based therapies, it is a “subtractive” approach intended to avoid added toxicity and side effects. Both treatments remain highly specialized and are offered at only a small number of medical institutions worldwide.

Safra Children’s Hospital

A dedicated pediatric facility providing comprehensive and compassionate care.

Key Departments

• Pediatric Intensive Care Unit
• Emergency Department
• Hemato-Oncology
• Neonatology
• Pediatric Neurology
• Gastroenterology and Nephrology
• Infectious Diseases
• Child Psychiatry
• Rare Diseases Institute

Specialized Services

• Pediatric Cardiology
• Stem Cell Research
• Developmental Care
• Metabolic Disorders Treatment

Edmond J. Safra International Congenital Heart Center

A leading center for cardiac care, offering:

• Advanced diagnostics
• Catheterization labs
• Multidisciplinary cardiac care
• Psychological support

Leviev Heart Center

A comprehensive cardiac facility integrating all aspects of heart care.

Key Divisions

• Cardiology
• Cardiac Surgery
• Electrophysiology
• Heart Failure Institute
• Cardiac Rehabilitation

Advanced Services

• Angiography and stenting
• Heart transplant care
• Non-invasive diagnostics
• Cardiac imaging research

Rehabilitation Hospital

A national leader in rehabilitation medicine offering:

Services

• Orthopedic rehabilitation
• Neurological rehabilitation
• Respiratory therapy
• Geriatric care
• Psychiatric services

Annual Capacity

• 190,000 outpatients
• 6,200 inpatients
• 621 beds

Advanced Therapies

• Hydrotherapy
• Physiotherapy
• Virtual Reality rehabilitation
• Speech therapy

Women’s Health & Maternity Center

A state-of-the-art facility focused on:

• Gynecologic oncology
• Fertility preservation
• IVF treatments
• Reproductive endocrinology

Sheba Longevity Center

Launched in 2025, Sheba Longevity Medicine 3.0 is the first center of its kind in the world operating inside an academic medical center. Rather than treating a specific disease, the program uses advanced genetic testing and roughly 400 biomarkers of aging to assess a patient’s biological age and generate a personalized profile of physical and cognitive function, then builds a yearlong intervention program aimed at improving and maintaining vitality.

Longevity 360

The Longevity 360 program runs across two visits followed by a year of structured follow-up:

First visit — comprehensive primary diagnosis, including a meeting with a longevity physician; biological age assessment based on genetics and metabolic markers; cognitive function assessment by a neuropsychologist; physical stamina assessment by physiotherapists (strength, stability, balance, and fitness); bone densitometry and body composition analysis; pulmonary function tests; ankle-brachial index and pulse wave velocity; audiometry; an oral health exam; a sleep study when needed; and, for women, a menopause assessment with a gynecologist.

Second visit — summary and custom plan. After Sheba’s multidisciplinary team analyzes the results, the patient meets with their longevity physician for a full explanation of their performance across every system tested, and leaves with a personal recommendations plan built around changes they can realistically implement.

Personal follow-up. Over the following year, the center’s team provides at least two remote consultations covering nutrition, cognitive health, physical therapy, and — for women — gynecology.

Institute for Screening, Prediction and Prevention

Sheba’s executive health institute goes beyond a standard physical, combining prevention and early disease detection with genetic and risk-factor testing for complex conditions. Every patient receives personal consultations with specialists in each field rather than a checklist of results. The annual checkup takes up to 5 hours for men and up to 7 hours for women, includes a comprehensive medical questionnaire completed before arrival, and ends with a same-day summary meeting; a complimentary breakfast is provided on-site after the initial blood draw.

The Annual Checkup Includes

• Full lab workup — CBC, liver and kidney function, lipid profile, glucose, HbA1c, electrolytes, blood proteins, CRP, iron, ferritin, TSH, vitamin B12, vitamin D, PSA (age-dependent), general urinalysis, and HIV antibodies on request
• Visit with an internist — medical history intake, physical examination, and recommendations
• Visit with a registered nurse, including blood pressure, visual acuity, and pupil dilation
• Body composition analysis (muscle, fat, and nerve mass)
• Eye exam — visual acuity, fundus exam, and intraocular pressure
• Cardiology — resting and stress ECG (ergometry) with a screening cardiologist, with an AI-based echocardiogram available on medical recommendation
• Hearing screening
• Oral medicine exam for tumors and precancerous lesions

Available at Extra Charge

Patients can add tests tailored to their own risk profile, among them colonoscopy (colon cancer screening, one test every 5 years after age 50), bone densitometry, echocardiogram, Holter monitor, mammogram and breast ultrasound with a breast surgeon, gynecologic exam and HPV testing, dermatologist skin cancer screening, low-dose chest CT for coronary calcium scoring and lung tumor detection, FibroScan for liver fibrosis, confocal microscopy for skin cancer, pharmacogenetic testing across 500 medications, BRCA1/BRCA2 genetic testing, VO2max testing, virtual catheterization (CT coronary angiography), liquid biopsy, EpiCheck bladder cancer screening, and PHI prostate health index testing.

Pricing (USD)

Prices are in USD and reflect Sheba’s published rates for the annual checkup and add-on tests. Added tests can only be purchased alongside the annual checkup, not on their own, and several (flagged in Sheba’s own materials as requiring medical recommendation) are scheduled only after physician review.

International Patient Services

Sheba Medical Center is a global destination for medical tourism, treating thousands of international patients annually.

Services Include

• Personalized treatment planning
• Dedicated patient coordinator
• Multilingual support (English, Russian, Arabic)
• Visa and travel assistance
• Accommodation arrangements
• Medical record coordination

360° Patient Care Approach

Sheba provides a full continuum of care:

Before Arrival

• Remote consultations
• Medical record review

During Treatment

• Access to advanced technologies
• Personalized care plans

After Treatment

• Follow-up care
• Rehabilitation support

Key Strengths

• Consistently ranked among the world’s top hospitals
• High patient satisfaction rates
• Access to advanced and innovative treatments
• Strong focus on research and development
• Comprehensive multidisciplinary care

Unique Advantages for International Patients

• Early access to advanced medications
• Transparent pricing structure
• Cultural sensitivity and multilingual support
• No additional service fees for medical tourism assistance

Conclusion

Sheba Medical Center stands as a global leader in healthcare, combining cutting-edge technology, world-class expertise, and a patient-centered approach. Its commitment to innovation, research, and compassionate care makes it a top choice for patients seeking advanced medical treatment and international healthcare services.